venBio Partners — 2020 Investments
3 investments dated 2020 · listed companies and verified rows first · show all
HealthtechNew York, US
Shawn Leland(Executive Officer, Director)Lori Hu(Director)Michael Caldwell(Director)
BoardSteven Elms(Executive Officer, Director, Promoter)
Board seatRichard Gaster· per SEC Form D · $65M raise · filed Nov 2020
RayzeBio develops radiopharmaceutical therapies for cancer treatment.
BiotechHealthtechMedical DevicesSan Diego, US
Ken Song(Executive Officer, Director)Ben Hickey(President)Abhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)
Board seatAaron Royston· per SEC Form D
Co-investorsSamsara BioCapitalScion Life SciencesSofinnova VenturesTCG CrossoverVersant VenturesVivo Capital+1 more
Tallac Therapeutics is a biopharmaceutical company developing oligonucleotide-based antibody drug conjugates (ADCs) to treat cancer, including its Toll-like Receptor Agonist Antibody Conjugates (TRAAC) that deliver a TLR9 agonist to activate immune responses within the tumor microenvironment.
BiotechHealthtechBurlingame, US
Board seatJaume PonsCorey Goodman· per SEC Form D
Co-investorsLightstone VenturesMRL Ventures FundMatrix Partners ChinavenBio Global Strategic
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.